{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:23:38Z","timestamp":1769610218180,"version":"3.49.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherche sur le SIDA et les H\u00e9patites virales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ViiV Healthcare France"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>M184V\/I NRTI resistance mutations can be selected by either lamivudine\/emtricitabine or abacavir. There are controversies about the use of abacavir\/lamivudine\/dolutegravir combinations in HIV-1-infected treatment-experienced patients with a fully suppressed HIV viral load (VL) and harbouring M184V\/I.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We assessed the efficacy of abacavir\/lamivudine\/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V\/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to integrase inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>A total of 154 patients with a fully suppressed HIV-1 plasma VL (&amp;lt;50\u2005copies\/mL) treated with tenofovir disoproxil fumarate\/emtricitabine\/boosted PI or abacavir\/lamivudine\/boosted PI who switched to an abacavir\/lamivudine\/dolutegravir regimen and had M184V\/I as a unique NRTI resistance mutation in their therapeutic history were retrospectively analysed up to 12\u2005months after the switch to abacavir\/lamivudine\/dolutegravir. Assessment of residual viraemia was performed at Months 1, 3, 6 and 12. Plasma VL with undetectable HIV-1 RNA corresponded to an absence of residual viraemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the 12\u2005months of follow-up, three patients had a blip of VL (53, 62 and 106\u2005copies\/mL) at Month 3 followed by a subsequent VL &amp;lt;50\u2005copies\/mL. No patient harboured a virological failure during the follow-up. Moreover, there was no change in residual viraemia during the follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>M184V\/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine\/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir\/lamivudine\/dolutegravir for at least 12\u2005months.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa019","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T20:09:48Z","timestamp":1579032588000},"page":"1290-1293","source":"Crossref","is-referenced-by-count":21,"title":["M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients"],"prefix":"10.1093","volume":"75","author":[{"given":"Aude","family":"Jary","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re \u2013 Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-8999","authenticated-orcid":false,"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re \u2013 Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, UMR1137, Inserm, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Wirden","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re \u2013 Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh P","family":"L\u00ea","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, UMR1137, Inserm, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, UMR1137, Inserm, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris, IAME, UMR1137, Inserm, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re \u2013 Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"2020042304563829600_dkaa019-B1","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.90.12.5653","article-title":"Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3\u2032-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase","volume":"90","author":"Tisdale","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020042304563829600_dkaa019-B2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1128\/AAC.41.5.1094","article-title":"Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89","volume":"41","author":"Tisdale","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042304563829600_dkaa019-B3","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/00002030-200308150-00008","article-title":"Clinically relevant interpretation of genotype for resistance to abacavir","volume":"17","author":"Brun-V\u00e9zinet","year":"2003","journal-title":"AIDS"},{"key":"2020042304563829600_dkaa019-B4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/315317","article-title":"Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group","volume":"181","author":"Harrigan","year":"2000","journal-title":"J Infect Dis"},{"key":"2020042304563829600_dkaa019-B5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/jac\/dkx018","article-title":"Switch as maintenance to elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate: week 48 results in a clinical cohort","volume":"72","author":"Perrier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020042304563829600_dkaa019-B6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2020042304563829600_dkaa019-B7","doi-asserted-by":"crossref","first-page":"ofy113.","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020042304563829600_dkaa019-B8","author":"De Miguel Buckley"},{"key":"2020042304563829600_dkaa019-B9","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020042304563829600_dkaa019-B10","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/5\/1290\/33112611\/dkaa019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/5\/1290\/33112611\/dkaa019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T08:57:51Z","timestamp":1587632271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/5\/1290\/5739466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,17]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa019","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,2,17]]}}}